Generex Biotechnology Corp. Granted Patents on New HPV and Influenza Vaccines

Publishing & Media

Share Tweet

Generex Biotechnology Corp. Granted Patents on New HPV and Influenza Vaccines

Generex Biotechnology Corp. (OTCQB: GNBT) stock volume soared Mar. 11, with 9,325,106 shares changing hands, significantly higher than its three-month average volume of 7,012,285 shares.

This surge in volume comes on the heels of the Worchester, Mass.-based bio-tech company’s Mar. 5 announcement that its wholly-owned subsidiary Antigen Express Inc. has received Notices of Allowance from the United States Patent Office relating to applications for the use of therapeutic vaccines targeting human papilloma virus (HPV) caused cancers as well as to potentially pandemic strains of influenza virus.

Generex has previously received allowances of broad claims surrounding the use of its Ii-Key hybrid technology platform. Both applications relate to vaccines designed using this platform, which was also used to design its AE37 vaccine that is currently in a late Phase II trial to prevent relapse in patients who have had breast cancer.

Moreover, the company has previously published preclinical studies on lead compounds targeting HPV and conducted clinical trials of influenza targeted vaccines in healthy volunteers. While there are prophylactic vaccines on the market to prevent HPV infection, none are approved for use in the therapeutic setting to treat existing cancers caused by HPV. The added potency of Antigen Express vaccines derives from its ability to activate CD4+ T helper cells, which are critical in the generation of a novel immune response.

Breast-Cancer Vaccine Trial

On Feb. 12, Generex promised it would be releasing the results on it breast-cancer vaccine trial at this year's American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago from May 30 to June 3, 2014. Ok, so if the news is good, why not share it with the shareholders now? Teasing them and potential investors with promises of information to be revealed at some future date is not a going to win many hearts and minds.

Like so many bio-tech penny stocks, Generex’s success is tied to terms and technologies that baffle the layperson. But what anyone can understand is its dismal financial, which haven’t been updated since Jul. 31, 2013. At that time, the company reported a -$8.5 million net income.

On Mar. 11, GNBT’s share price closed 4 cents, unchanged from share price of the previous day.

Find out what could be the best investor’s move when it comes to GNBT by getting the complete report here, or by cutting and pasting the following link in your Web browser:


Global Links Corp. to Distribute New Line of Hemp-Based Beauty Products

In other news, Global Links Corp. (OTCPINK: GLCO) share volume was strong Mar. 11, with 6,007,601 shares changing hands on news.

The Las Vegas-based barter company’s share volume soared probably as a result the announcement the same day  that Global Link’s wholly-owned subsidiary, Hemp Life Today LLC has reached an agreement with Easton Pharmaceuticals Inc. to jointly develop and distribute an exclusive line of health and beauty hemp-based products on

The agreement outlines that Easton Pharmaceuticals will design new and innovative hemp-based products which Hemp Life Today will market and distribute worldwide through its product website. The first hemp product to be offered on will be Easton Pharmaceutical's newly developed Hempstral SA, an anti-aging skin moisturizer designed to combat and prevent premature aging and sun damaged skin.

Hempstral SA consists of high quality hemp oil which can now be legally obtained from US based producers and will be showcased at the Total Health Show in Toronto this April. Hempstral SA is transdermally delivered through skin tissue using Easton Pharmaceuticals' transdermal delivery matrix and formulations, which are patented or patent pending. Both companies plan to introduce other hemp-based products utilizing this technology moving forward.

This is just the latest piece of good news coming from the company.

Canceling Shares

On Feb. 25, Global Links announced the cancellation of 150,000,000 shares of its common stock, or 24% of the current number of shares issued and outstanding. Following this action, Global Links shares outstanding will equal 478,071,388.

"Global Links has significant growth and acquisition opportunities coming in the near future and it's in our best interest to ensure that our shares are more tightly held right now. By cancelling a quarter of our outstanding shares, we are putting the company in a much stronger position for future acquisitions while simultaneously enhancing the value of our existing shareholder interest. We look forward to announcing positive and exciting business developments in the coming weeks," stated President of Global Links Frank Dobrucki, in a written statement.

Launches Network for Cannabis Industry

Then on Feb. 26, the company announced its wholly-owned subsidiary, Hemp Life Today LLC, has launched a proprietary business networking platform for the Cannabis industry called

Hemp Life Today's site will operate similarly to other major business networking organizations, collecting membership dues and planning monthly events that revolve around issues pertinent to the Hemp and Medical Marijuana industry. The first chapter of will be located in Tampa, FL, home of ‘Medical Marijuana Tampa,' the state's first cannabis college.

This move came less than a week from Global Links’ announcement that its wholly-owned subsidiary, Hemp Life Today LLC, is set to launch a new product, "The Hemp Life Today Complete Medical Marijuana Retail Dispensary Kit™" on its website,

Written by attorneys, the company's Medical Marijuana Retail Dispensary Kit provides an all-inclusive, step-by-step process for opening and operating a legal dispensary in United States. The kit provides information on every vital aspect of opening a medical marijuana dispensary, including topics such as incorporation, the naming process, state laws, the buying and selling process, management of business operations, selecting a location, providing customer service and several more.

On Mar. 11, AVNR’s share price closed at 8 cents unchanged from its share price of the previous day.

Find out what could be the best investor’s move when it comes to AVNR by getting the complete report here, or by cutting and pasting the following link in your Web browser:


Bioheart Stock Volume Soars on Positive News

Meanwhile, development-stage, biotechnology company Bioheart Inc.’s (OTCQB: BHRT) stock volume was robust Mar. 11, with 3,430,364 shares changing hands, substantially higher than its three-month average volume of 2,415,259 shares.

The surge in volume is being fueled in part by the Sunrise, Fla.-based company’s Mar. 4 announcement on the positive results of 6 months of data from its phase I ANGEL Trial.

Positive Data on Trial

Fully funded by Bioheart, the trial is being conducted in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute. 

"The six month data has far exceeded our expectations. We were excited to see that patients continued to improve from 3 months to 6 months demonstrating the power of a biological product which can actually remodel tissue and change the course of a disease,” said Kristin Comella, Bioheart's chief science officer, in a written statement. “This phase I study will provide necessary safety and preliminary efficacy of adipose derived stem cells in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months,” she added.

At the 6 month time point, patients are demonstrating an average improvement in exercise capacity or a six minute walk test of approximately 68 meters as compared to an average improvement of 47 meters at 3 months. Eighty percent of the patients showed an improvement in their exercise capacity from 3 months to 6 months post stem cell injection.

On Mar. 11, BHRT’s share price closed 4 cents, up 1 cent from share price of 3 cents the previous day.

Find out what could be the best investor’s move when it comes to BHRT by getting the complete report here, or by cutting and pasting the following link in your Web browser:


ABOUT US: issues momentum alerts on stocks that can provide gains to day traders. provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.  monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:

Disclosure is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.